Jeff Hrkach

859 total citations
8 papers, 449 citations indexed

About

Jeff Hrkach is a scholar working on Pulmonary and Respiratory Medicine, Biomaterials and Molecular Biology. According to data from OpenAlex, Jeff Hrkach has authored 8 papers receiving a total of 449 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 4 papers in Biomaterials and 3 papers in Molecular Biology. Recurrent topics in Jeff Hrkach's work include Nanoparticle-Based Drug Delivery (3 papers), Radiopharmaceutical Chemistry and Applications (3 papers) and Prostate Cancer Treatment and Research (3 papers). Jeff Hrkach is often cited by papers focused on Nanoparticle-Based Drug Delivery (3 papers), Radiopharmaceutical Chemistry and Applications (3 papers) and Prostate Cancer Treatment and Research (3 papers). Jeff Hrkach collaborates with scholars based in United States and United Kingdom. Jeff Hrkach's co-authors include Róbert Langer, André E. Nel, Anil K. Patri, Piotr Grodzinski, Nicholas J. Panaro, Robert J. Lee, Vladimir P. Torchilin, William C. Zamboni, Joseph P. Vacanti and George A. Taylor and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and The Annals of Thoracic Surgery.

In The Last Decade

Jeff Hrkach

7 papers receiving 438 citations

Peers

Jeff Hrkach

BIOMA

BE

SURGE

MB

PRM

Ning Gao United States

Biqiong Wang China

Hecheng Ma China

K. Wang China

Heping Qiu China

Zhiting Sun China

Qingqing Sang China

Zhouxue Wu China

Young-Wook Won South Korea

Federica De Lorenzi Germany

Ning Gao United States

Jeff Hrkach

222 ×0.7

BIOMA

204 ×1.1

BE

120 ×0.8

SURGE

158 ×1.4

MB

26 ×0.7

PRM

Citations per year, relative to Jeff Hrkach Jeff Hrkach (= 1×) peers Ning Gao

Countries citing papers authored by Jeff Hrkach

Since Specialization

Citations

This map shows the geographic impact of Jeff Hrkach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeff Hrkach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeff Hrkach more than expected).

Fields of papers citing papers by Jeff Hrkach

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeff Hrkach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeff Hrkach. The network helps show where Jeff Hrkach may publish in the future.

Co-authorship network of co-authors of Jeff Hrkach

This figure shows the co-authorship network connecting the top 25 collaborators of Jeff Hrkach. A scholar is included among the top collaborators of Jeff Hrkach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeff Hrkach. Jeff Hrkach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Hrkach, Jeff & Róbert Langer. (2020). From micro to nano: evolution and impact of drug delivery in treating disease. Drug Delivery and Translational Research. 10(3). 567–570. 33 indexed citations

2.

Lam, Michael Hon‐Wah, Young Ho Song, Hong Wang, et al.. (2015). Abstract C197: Accurins improve the pharmacokinetics, pharmacodynamics, tolerability and anti-tumor activity of the AKT inhibitor MK-2206. Molecular Cancer Therapeutics. 14(12_Supplement_2). C197–C197.

3.

Barry, Simon T., Elaine Cadogan, Rajesh Odedra, et al.. (2014). Abstract 5409: AZD1152-hQPA Accurins: Nanoparticle formulations showing extended release and the potential for improved therapeutic index. Cancer Research. 74(19_Supplement). 5409–5409. 2 indexed citations

4.

Low, Susan C., Daniel D. Von Hoff, Monica Mita, et al.. (2014). Abstract 911: Prostate-specific membrane antigen (PSMA) expression as a potential patient selection marker in patients with refractory solid tumors administered BIND-014, a PSMA-targeted nanoparticle containing docetaxel. Cancer Research. 74(19_Supplement). 911–911. 2 indexed citations

5.

Hoff, Daniel D. Von, Monica Mita, Peter D. Eisenberg, et al.. (2013). Abstract LB-203: A phase I study of BIND-014, a PSMA-targeted nanoparticle containing docetaxel, in patients with refractory solid tumors.. Cancer Research. 73(8_Supplement). LB–203. 5 indexed citations

6.

Summa, Jason M., et al.. (2012). Abstract LB-452: A phase I, open label, safety, pharmacokinetic and pharmacodynamic dose escalation study of BIND-014 given by IV infusion to patients with advanced or metastatic cancer. Cancer Research. 72(8_Supplement). LB–452. 4 indexed citations

7.

Zamboni, William C., Vladimir P. Torchilin, Anil K. Patri, et al.. (2012). Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance. Clinical Cancer Research. 18(12). 3229–3241. 194 indexed citations

8.

Shum‐Tim, Dominique, Ulrich A. Stock, Jeff Hrkach, et al.. (1999). Tissue engineering of autologous aorta using a new biodegradable polymer. The Annals of Thoracic Surgery. 68(6). 2298–2304. 209 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact